Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Abstract Background Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-posi...

Full description

Bibliographic Details
Main Authors: Anne Julienne Genuino, Usa Chaikledkaew, Anna Melissa Guerrero, Thanyanan Reungwetwattana, Ammarin Thakkinstian
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Health Services Research
Subjects:
Adjuvant trastuzumab
Cost-utility analysis
HER2-positive
Breast cancer
Cost-effectiveness
Philippines
Online Access:http://link.springer.com/article/10.1186/s12913-019-4715-8

Internet

http://link.springer.com/article/10.1186/s12913-019-4715-8

Similar Items